We found that Vorinostat, the most-used HDAC inhibitor currently in clinical trials for GBM (42), at its 2D IC50 concentration (13.43 μM) increased migration and proliferation in the beginning phase as well as towards the end of the 168-h study. The gene discussed is HDAC9; the disease is glioblastoma.